Hosted by Dailymotion. For legal issues report at the Copyright Center, report us on DMC, or use the Instant Removal tool.
A New Merck Acquisition
Description
Merck & Co ($MRK@US) has agreed to purchase drugmaker Acceleron Pharma Inc ($XLRN@US) for $11.5 billion. Merck is completing the purchase so that it can bolster its portfolio and add drugs for rare diseases to its lineup. The deal calls for Merck to pay $180 per share for Acceleron, a premium of around 2.6%. The acquisition also allows Merck to market and sell rare disease drug Sotatercept in addition to its cancer drug Keytruda. Merck stock ticked almost $2 higher in early trading.
More from User
01:02
Karp Sounds Reg Alarm
Benzinga
01:02
SEC Kills PDT
Benzinga
00:56
Walmart Adds Subway Delivery
Benzinga
00:55
GLP-1s Fuel Return Surge
Benzinga
00:52
Hegseth Firm On Anthropic
Benzinga
01:05
Lululemon Falls On Outlook
Benzinga
Related Videos
06:06
Leading Biotechnology Company, Biopharmaceutical Sector | Concord Biotech LTD
concordbiotech
00:05
PDF Risk Management Applications in Pharmaceutical and Biopharmaceutical Manufacturing EBook
Albrechtsen 714
00:56
SriSai Biopharmaceutical Solutions
Bartesperanzatrevino
00:06
Download Biopharmaceutical Production Technology 2 Volume Set Ebook Online
Broeks
02:16
Medicine Book Review: Preclinical Development Handbook: ADME and Biopharmaceutical Properties (Pharmaceutical Development Series) by Shayne Cox Gad
MedicineBooks
05:00
Pharmaniaga first locally owned biopharmaceutical plant
The Star